Therapy Areas: AIDS & HIV
PathogenDx Awarded Second NIH Grant to Develop More Accurate and Faster COVID-19 Testing
17 August 2020 - - US-based technology company PathogenDx, Inc has received a second grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the National Institutes of Health to develop more accurate and efficient COVID-19 diagnostic testing technology, the company said.

The grant was issued under the NIH's Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) PAR-20-178 two year Research Project Grant Program and will be used to expedite the research and development of PathogenDx's patented DetectX-Rv microarray.

In the next year, PathogenDx aims to utilize the additional funding to accomplish the following four goals: capture and identify new COVID-19 mutations; improve the sensitivity and specificity analysis of existing tests; improve testing turnaround by simplifying the detection of COVID-19; enhance detection and diagnose asymptomatic transmission.

Under an expedited research and development timeline, PathogenDx is on track to meet these milestones before the end of the two year time frame.

Research reported in this publication was supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI158068.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Headquartered in Scottsdale, Arizona, PathogenDx's mission is to become the new standard in DNA-based testing through widespread adoption of its advanced microarray testing platform for the agriculture, food and health diagnostics industries.

PathogenDx's technology can rapidly identify and detect multiple pathogens all in a single test, in six hours providing triplicate data per analyte for certainty in results with a simple and easy process.

The company's DNA-testing products DetectX, QuantX, and EnviroXare disrupting the century-old practice of petri-dish testing and qRT-PCR molecular platform to identify, detect and quantify pathogens.
Login
Username:

Password: